Evidence map›Paper›PMID 26059289›Full record

ReviewDrugs2015

Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.

Ulrike Hostalek, Mike Gwilt, Steven Hildemann

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03848533 (Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes), which is not on this map. Cited by 110 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
110citing papers in PubMed, 8 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03848533 phase2unknown statusstarted 2019, after this paper: background citation

Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study

Ran2019Enrolled42Registered outcomes19Posted comparisons0ConditionsPrediabetesArmsMelatonin, Metformin, Placebo
PMID 27653034PMID 21241070PMID 17013468PMID 20701406PMID 7601013PMID 22722338PMID 17874238PMID 24792719PMID 24778463PMID 24283301PMID 24251676PMID 23775102other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

110 citing papers in PubMed, 8 syntheses or guidelines pooled it, 268 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Influence of Solute Carrier Family 22 Member 1 (Current diabetes reviews · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Review
  19. Article
  20. Review

50 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Ulrike HostalekMerck KGaA, Darmstadt, Germany.
Mike Gwilt
Steven Hildemann
Merck (Germany) · DEShrewsbury College · GBUniversitäts-Herzzentrum Freiburg-Bad Krozingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

People with elevated, non-diabetic, levels of blood glucose are at risk of progressing to clinical type 2 diabetes and are commonly termed 'prediabetic'. The term prediabetes usually refers to high-normal fasting plasma glucose (impaired fasting glucose) and/or plasma glucose 2 h following a 75 g oral glucose tolerance test (impaired glucose tolerance). Current US guidelines consider high-normal HbA1c to also represent a prediabetic state. Individuals with prediabetic levels of dysglycaemia are already at elevated risk of damage to the microvasculature and macrovasculature, resembling the long-term complications of diabetes. Halting or reversing the progressive decline in insulin sensitivity and β-cell function holds the key to achieving prevention of type 2 diabetes in at-risk subjects. Lifestyle interventions aimed at inducing weight loss, pharmacologic treatments (metformin, thiazolidinediones, acarbose, basal insulin and drugs for weight loss) and bariatric surgery have all been shown to reduce the risk of progression to type 2 diabetes in prediabetic subjects. However, lifestyle interventions are difficult for patients to maintain and the weight loss achieved tends to be regained over time. Metformin enhances the action of insulin in liver and skeletal muscle, and its efficacy for delaying or preventing the onset of diabetes has been proven in large, well-designed, randomised trials, such as the Diabetes Prevention Program and other studies. Decades of clinical use have demonstrated that metformin is generally well-tolerated and safe. We have reviewed in detail the evidence base supporting the therapeutic use of metformin for diabetes prevention.

Indexed as

Diabetes Mellitus, Type 2HumansHypoglycemic AgentsMetforminPrediabetic StateHypoglycemic AgentsMetformin

Identifiers

PMID26059289
PMCPMC4498279
OpenAlexW564948178

What Socratic holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.